Multiplexed assay technologies make up 25% of the total microarrays market - approaching $1.5 billion - and is projected to grow 50% annually over the next 5 years.

Multiplexed assays are an important prevailing technology, specifically in the pharmacogenomics arena for drug discovery and clinical diagnostics purposes. As the pharmaceutical industry evolves its business model in accordance with the development of drugs for stratified disease markets, significant growth is anticipated for personalized medicine. The ability to align drug development with these market segments will be critically dependent on emerging SNP-genotyping and protein profiling practices. The concept of such profiling requires the assay of multiple RNA strands and proteins. Ideally, such assays should be conducted within the same sample, in order to reduce costs as well as error. Old school microarrays are less well suited to meet these demands, which has spurred the development of assays capable of such high density multiplexing.

Scope

This is the only publication focused solely on the increasing commercial interest in multiplexed assay technologies. This Report is essential reading for those decision-makers in the pharmaceutical, biotechnology, and clinical diagnostic industries.

D&MD's High Density Multiplexed Assays Market Analysis Report identifies both the technological and strategic reasons in support of high density multiplexed assay technologies becoming a major player in disease and patient stratification over the next five years, especially in major areas such as cancer.

Market Opportunities

• Utilize multiplexed assay technology in the pharmacogenomics arena for efficient and effective means of drug discovery and clinical diagnostics.†
• Discover and profile characteristic surrogate panels and combinatorial drug compound libraries in order to impact the trends stratifying patients for specific therapeutic treatments, diagnosis, and the prognosis of disease.
• Gain market leverage through the application of multiplexed assay technologies to SNP-genotyping and protein profiling by establishing strategic alliances with organizations having access to databases of proprietary SNPs and haplotypes, as well as to protein biomarkers.
• Transform the traditional phenotype-based disease management of cancer through the use of multiplexed assays tools.

Key Reasons to Buy

• Determine the competitive advantage of high density multiplexed assay technologies over their microarray counterparts through a comprehensive breakdown of the capabilities and limitations of both.
• Discover the commercial viability of high density multiplexed assay technologies via a thorough analysis of their widespread applications.
• Pinpoint the full market potential of multiplexed assay technologies with an examination of the projected applicatory impact through 2008.
• Gain insight into the business strategies of key industry players through in-depth analyses of their technologies, including strengths and weaknesses, product pipelines, alliances, and more.
• Learn about patenting multiplexed technologies with an assessment of the patent landscape, including current patents and their holders.